Taigen Biopharmaceuticals Holdings Ltd (4157) — Free Cash Flow Generation Index
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Free Cash Flow Generation Index of 0.84x as of March 2026. Free cash flow of NT$92.91 Million represents 1% of operating cash flow (NT$111.04 Million). Explore capital reinvestment ratio of Taigen Biopharmaceuticals Holdings Ltd to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Taigen Biopharmaceuticals Holdings Ltd Free Cash Flow Generation Index (2021–2025)
Historical FCF Generation Index trend for Taigen Biopharmaceuticals Holdings Ltd across 3 annual periods. For the full cash flow conversion analysis, see 4157 operating cash flow.
Annual Free Cash Flow Generation for Taigen Biopharmaceuticals Holdings Ltd (2021–2025)
Year-by-year Free Cash Flow Generation Index for Taigen Biopharmaceuticals Holdings Ltd. Check Taigen Biopharmaceuticals Holdings Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (TWD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.78x | NT$16.42 Million | NT$20.93 Million | NT$4.50 Million | ▲ +21.9% |
| 2023 | 0.64x | NT$13.35 Million | NT$20.74 Million | NT$7.39 Million | ▼ -34.4% |
| 2021 | 0.98x | NT$617.24 Million | NT$629.07 Million | NT$11.83 Million | — |